X denotes truncating mutation. PEST2 domain 345–377; UBA domain 387–436. *Two different mutations reported to cause this truncation. ‡ Results from splice site mutations (intron 7 ...

They estimated that the increased risk of mouth cancer from sugary drinks would lead to three more cases of the disease per 100,000 people. The scientists, who published their findings in the ...

Diagnosis of PDB is a combination of clinical evaluation, imaging and histopathological assessment. If an underlying cancer is suspected, a sentinel lymph node biopsy may be done to assess the spread ...

How many deaths have been linked to the mystery disease in Congo? At least 60 deaths have been reported, according to the latest bulletin from the WHO's Africa office. In the initial outbreak ...

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, 6-5-1, Kashiwanoha, Kashiwa-City, Chiba 277-8577, Japan ...

skku.edu There has been limited evidence for the association between chronic obstructive pulmonary disease (COPD) and the incidence of lung cancer among never smokers. We aimed to estimate the risk of ...

During the latest installment of the “Calm Down’ podcast, the Fox Sports veteran NFL sideline reporter explained that she’s working through a pre-skin cancer issue on her upper lip.

A blood test that detects tiny fragments shed by bowel cancer cells could help catch the disease at its earliest stage, increasing the chances of survival. The test scans the bloodstream ...

At least 1,318 people have exhibited symptoms and 53 have died, the WHO said. The U.S. Centers for Disease Control and Prevention is closely monitoring an unknown disease that has killed dozens in ...

About 18 years ago, a 4-year-old girl with a rare nerve cell cancer received an infusion of immune cells that were genetically engineered to fight the disease. Since then, she has remained cancer ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer — achieving the efficacy goals of a Phase 3 study.